Ro7663498

Phase 1

Roche

Ro7663498 is one of 27 therapeutic programs targeting Diabetic Retinopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic RetinopathyRecruiting

Diabetic RetinopathyPhase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Avapro

Sanofi

Approved

1 3

Farxiga

Tricor

3 5

EGRIFTA WR

TTheratechnologies

Approved

1 6

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 7

Decadron

AAspen Global Incorporated

Glucophage

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lodosyn

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Diabetic Retinopathy

NCT07588100

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

A Multicenter, Non-Randomized, Open-Label, Multiple-Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Recruiting· Roche logo

Roche·Phase 1·NCT07588100·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ro7663498. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ro7663498. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Roche

Ro7663498

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News